KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Depreciation & Amortization (CF) (2016 - 2025)

Pfizer (PFE) has disclosed Depreciation & Amortization (CF) for 17 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Depreciation & Amortization (CF) changed N/A to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 billion through Dec 2025, up 26.26% year-over-year, with the annual reading at $6.6 billion for FY2025, 6.0% down from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $1.7 billion at Pfizer, up from $1.7 billion in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $3.9 billion in Q4 2021, with the low at $1.2 billion in Q3 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $1.8 billion, with a median of $1.6 billion recorded in 2025.
  • Peak annual rise in Depreciation & Amortization (CF) hit 33.87% in 2023, while the deepest fall reached 55.99% in 2023.
  • Over 5 years, Depreciation & Amortization (CF) stood at $3.9 billion in 2021, then dropped by 8.07% to $3.5 billion in 2022, then tumbled by 52.89% to $1.7 billion in 2023, then grew by 5.09% to $1.8 billion in 2024, then dropped by 3.87% to $1.7 billion in 2025.
  • According to Business Quant data, Depreciation & Amortization (CF) over the past three periods came in at $1.7 billion, $1.7 billion, and $1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.